Tag: availability

Simplified capital structure bolsters ability to rapidly meet customer demand, reduce interest expense, and increase liquidity

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

TALLINN, Estonia, June 15, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain built for speed, accessibility, and long-term sustainability, has officially entered the seventh phase of its token presale, with the public launch now just weeks away. With over $4.5 million already raised and more than 11,500 participants onboard, momentum is surging.

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx¹.

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), is providing this bi-weekly update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"). On May 2, 2025, the Company announced that there would be a delay in the filing of its annual financial statements, management’s discussion and analysis and related CEO and CFO certificates for the fiscal year ended December 31, 2024 (collectively, the “Annual Filings”), as required under applicable Canadian securities laws (the "Default Announcement"). As stated in the Default Announcement, the Company expects to complete the Annual Filings by June 30, 2025.

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 

CALGARY, Alberta, June 13, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto") announces the retirement of Michael (Mick) MacBean as a director and confirms the monthly dividend with respect to June 2025 of $0.11 per common share is to be paid on July 15, 2025, for shareholders of record on June 30, 2025. Dividends paid by Peyto to Canadian residents are eligible dividends for Canadian income tax purposes.